{"id":"comparator-glipizide","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Nervousness"},{"rate":"2-5","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL1073","moleculeType":"Small molecule","molecularWeight":"445.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glipizide is a meglitinide-class insulin secretagogue that binds to sulfonylurea receptors on the ATP-sensitive potassium channels in pancreatic beta cells. This binding closes the potassium channels, leading to cell depolarization and opening of voltage-gated calcium channels, which triggers insulin release. It is used to lower blood glucose in type 2 diabetes by increasing endogenous insulin secretion.","oneSentence":"Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:03.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00094770","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1172},{"nctId":"NCT00543010","phase":"PHASE3","title":"MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-11","conditions":"Diabetes Mellitus, Type 2","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":488,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glipizide"],"phase":"phase_3","status":"active","brandName":"Comparator: glipizide","genericName":"Comparator: glipizide","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}